Publication:
Large-scale proteomic analysis of patients with type 2 diabetes mellitus and atherosclerosis using a label-free LC-MS/MS approach

dc.contributor.coauthorSurmen, Mustafa Gani
dc.contributor.coauthorBozkaya, Tijen Alkan
dc.contributor.coauthorSurmen, Saime
dc.contributor.coauthorCakici, Cagri
dc.contributor.coauthorPence, Sadrettin
dc.contributor.coauthorEmekli, Nesrin
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAteş, Mehmet Şanser
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:28:29Z
dc.date.issued2023
dc.description.abstractObjective: Type 2 diabetes mellitus (T2D) is a metabolic disease whose molecular events have not yet been fully clarified. However, next-generation powerful molecular approaches such as mass spectrometry (MS)-based proteomics holds promise. In this study, we aimed to reveal the protein profile of serum samples obtained from patients with T2D and atherosclerotic cardiovascular disease using the high-resolution liquid chromatography (LC)-MS/MS system. Materials and Methods: Immune depletion was performed for the top 12 abundant proteins in 10 µl serum samples taken from individuals. Then, tryptic peptides were obtained from total proteins by applying a digestion protocol. Accordingly, reduction, alkylation, and digestion with trypsin enzyme were carried out, respectively. Tryptic peptides were analyzed in an ultra-high-pressure LC-MS/MS system with a label-free proteomic approach. The raw data were processed using the software program. Results: LC-MS/MS analyses revealed 120 proteins with significant expression changes. Some of these proteins were associated with inflammation, lipid transport, and oxidative stress, which are known to play an important role in T2D and its complications. Conclusion: As a result, LC-MS/MS analyses highlighted the proteins that will provide predictions in the treatment and course of T2D. We believe that validation of these proteins with targeted proteomic approaches in a larger sample in further studies will contribute to the development of clinically usable panels.
dc.description.indexedbyScopus
dc.description.indexedbyTR Dizin
dc.description.issue1
dc.description.publisherscopeNational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipFinancial Disclosure: This study was supported by Istanbul Medipol University Scientific Research Projects (Project Number: 2019/16).
dc.description.volume13
dc.identifier.doi10.26650/experimed.1219362
dc.identifier.issn2667-5846
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85173962083
dc.identifier.urihttps://doi.org/10.26650/experimed.1219362
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25734
dc.keywordsAtherosclerosis
dc.keywordsDiabetes
dc.keywordsMass spectrometry
dc.keywordsProteomics
dc.keywordsSerum
dc.language.isoeng
dc.publisherIstanbul University Press
dc.relation.grantnoİstanbul Medipol Üniversitesi, IMU, (2019/16)
dc.relation.ispartofExperimed
dc.subjectMedicine, general and internal
dc.titleLarge-scale proteomic analysis of patients with type 2 diabetes mellitus and atherosclerosis using a label-free LC-MS/MS approach
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAteş, Mehmet Şanser
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05352.pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format